The prevalence of blood cancers, which include leukemia, lymphoma, and myeloma (among others), represents a significant global health concern. In recognition of Blood Cancer Awareness Month, this September, Editors from across our hybrid and OA oncology journals have chosen the following articles to highlight the latest advances in blood cancer research.
- Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML)
- Real-world treatments and thrombotic events in polycythemia vera patients in the USA
- Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia
- Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies
- Global burden of hematologic malignancies and evolution patterns over the past 30 years
- Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
- Management of chronic myeloid leukemia in 2023 – common ground and common sense
- Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
- The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review
- Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT
- Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS
- Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era
- The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT
- Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse
Experimental Hematology & Oncology
- Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing
- The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives
- Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial
Journal of Hematology & Oncology
- Recent advances in targeted therapies in acute myeloid leukemia
- Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
- The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades
- AML classification in the year 2023: How to avoid a Babylonian confusion of languages
- Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
- Dual intron-targeted CRISPR-Cas9-mediated disruption of the AML RUNX1-RUNX1T1 fusion gene effectively inhibits proliferation and decreases tumor volume in vitro and in vivo
- The KMT2A recombinome of acute leukemias in 2023
- Whole genome sequencing provides comprehensive genetic testing in childhood B-cell acute lymphoblastic leukaemia
Poster image: © Jennifer / Stock.adobe.com.